Drug discovery and development for rare genetic disorders

Area of Science:

• Pharmacology
• Genetics
• Biotechnology

Background:

• Millions affected by ~7,000 rare diseases in the US.
• Significant gap exists between rare disease research and clinical application.
• Urgent need for accelerated drug development for orphan diseases.

Purpose of the Study:

• Review state-of-the-art drug discovery strategies for rare diseases.
• Evaluate small molecule and biologic approaches for orphan diseases.
• Highlight the role of pharmacogenetics, sequencing, and biomarkers.

Main Methods:

• Review of small molecule screening (high throughput, target-based, phenotypic).
• Evaluation of drug repurposing for accelerated clinical trials.
• Survey of biologics (gene therapy, recombinant proteins, transplants) and disease models (animal, iPSCs).

Main Results:

• Pharmacogenetics and whole genome sequencing are crucial for genetic rare diseases.
• Drug repurposing offers a faster route to clinical trials.
• Biomarkers are essential throughout drug discovery and development.

Conclusions:

• Multiple strategies, including small molecules, biologics, and advanced genetic techniques, can accelerate rare disease drug development.
• Integrating pharmacogenetics, drug repurposing, and robust disease models is vital.
• Biomarker utilization is critical for efficient clinical translation.